Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2090877 | 0.98 | L3MBTL1 (0.57) | L3MBTL1TDP1IDO1KDM4ELMNA | |
| SCHEMBL791465 | 0.98 | L3MBTL1 (0.57) | L3MBTL1TDP1IDO1KDM4ELMNA | |
| SCHEMBL12982429 | 0.98 | L3MBTL1 (0.57) | L3MBTL1TDP1IDO1KDM4ELMNA | |
| SCHEMBL8498124 | 0.98 | L3MBTL1 (0.57) | L3MBTL1TDP1IDO1KDM4ELMNA | |
| SCHEMBL8500355 | 0.98 | L3MBTL1 (0.57) | L3MBTL1TDP1IDO1KDM4ELMNA | |
| SCHEMBL8496079 | 0.98 | L3MBTL1 (0.57) | L3MBTL1TDP1IDO1KDM4ELMNA | |
| SCHEMBL8499737 | 0.98 | L3MBTL1 (0.57) | L3MBTL1TDP1IDO1KDM4ELMNA | |
| SCHEMBL8499359 | 0.98 | L3MBTL1 (0.57) | L3MBTL1TDP1IDO1KDM4ELMNA | |
| SCHEMBL8499231 | 0.98 | L3MBTL1 (0.57) | L3MBTL1TDP1IDO1KDM4ELMNA | |
| SCHEMBL8496478 | 0.98 | L3MBTL1 (0.57) | L3MBTL1TDP1IDO1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020018087-A1 | POLYURETHANE FOAM ADDITIVES TO IMPROVE FOAM ADHESION TO ORGANIC POLYMERS | EVONIK DEGUSSA GMBH (DE) | 2020-01-23 | — | — | WO | claimed |
| JP-11199890-A | — | — | None | — | — | JP | disclosed |
| US-20250154334-A1 | EFFICIENT CHEMICAL RECYCLING METHOD FOR WASTE POLYESTER FABRICS | NAN YA PLASTICS CORPORATION (TW) | 2025-05-15 | — | — | US | disclosed |
| CN-119977795-A | Efficient chemical recovery method for waste polyester fabrics | 南亚塑胶工业股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| US-20240308939-A1 | BI-FUNCTIONALIZED DICYCLOPENTADIENE MONOMER AND POLYMER EMBODIMENTS, AND METHODS OF MAKING AND USING SAME | UVIC INDUSTRY PARTNERSHIPS INC. (CA) | 2024-09-19 | — | — | US | disclosed |
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023097251-A1 | OLIGONUCLEOTIDE-CONTAINING TRANSCRIPTION FACTOR TARGETING CHIMERAS | YALE UNIVERSITY (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023285883-A1 | BI-FUNCTIONALIZED DICYCLOPENTADIENE MONOMER AND POLYMER EMBODIMENTS, AND METHODS OF MAKING AND USING THE SAME | UVIC INDUSTRY PARTNERSHIPS INC. (CA) | 2023-01-19 | — | — | WO | disclosed |
| US-20220402907-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | YALE UNIVERSITY | 2022-12-22 | — | — | US | disclosed |
| US-11021492-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| WO-1998043649-A2 | AGE PRODUCTION INHIBITORY COMPOSITION COMPRISING A MAILLARD REACTION INHIBITOR AND VITAMIN B¿6? | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-08 | — | — | WO | disclosed |
| US-5719176-A | 2-amino-1,3-propanediol compound and immunosuppressant | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1998-02-17 | — | — | US | disclosed |
| US-5677322-A | THERAPY FOR AGING, DIABETES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-10-14 | — | — | US | disclosed |
| US-5604229-A | 2-amino-1,3-propanediol compound and immunosuppressant | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-02-18 | — | — | US | disclosed |
| EP-0638075-A1 | THIAZOLE OR IMIDAZOLE DERIVATIVES AS MAILLARD REACTION INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-02-15 | — | — | EP | disclosed |
| EP-0627406-A1 | 2-AMINO-1,3-PROPANEDIOL COMPOUND AND IMMUNOSUPPRESSANT | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1994-12-07 | — | — | EP | disclosed |
| WO-1994019335-A1 | THIAZOLE OR IMIDAZOLE DERIVATIVES AS MAILLARD REACTION INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-09-01 | — | — | WO | disclosed |
| US-5155113-A | Administering 5-fluorouracil and derivatives with pyridine and pyridone derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-10-13 | — | — | US | disclosed |
| EP-0180188-B1 | A COMPOSITION FOR INCREASING THE ANTI-CANCER ACTIVITY OF AN ANTI-CANCER COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-15 | — | — | EP | disclosed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402907-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | L3MBTL1 785/4885TDP1 541/4885IDO1 3168/4885 |
| US-20240308939-A1 | BI-FUNCTIONALIZED DICYCLOPENTADIENE MONOMER AND POLYMER EMBODIMENTS, AND METHODS OF MAKING AND USING SAME | PUF60, MTHFD2, THEM6 | L3MBTL1 2423/4885TDP1 902/4885IDO1 447/4885 |
| US-11021492-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | L3MBTL1 1721/4885TDP1 3445/4885IDO1 4623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.